Deasy Halik, Rina Masadah, Berti Nelwan, Halidah Rahawarin, Andi Alfian Zainuddin, Syamsul Rijal


Ovarian cancer is the eight most common caused of death of women malignancy disease in the world. Many of cases have been found in advanced stages with metastatic. Early detection of metastatic would be helpful to perform optimal prevention and therapy in order to increase morbidity and mortality rates. Mesenchymal Epithelial Transition Factor Receptor (C-met) with its Hepatocyte growth factor/ Scatter factor ligand (SF) is a membrane receptor that stimulate cell proliferation, differentiation, motility, and invasion, through mitogenic intracellular signalling.

The purpose of this study was to evaluate the role of c-met in progression of serous ovarian carcinoma (SOC) by histopathological grading. We did retrospective cross-sectional study to 82 samples of serous ovarian carcinoma which consist of low-grade SOC and high-grade SOC, using immunohistohemical analysis. The analysis revealed that there were no significant differences (p=0.184) between expression of c-met in low-grade SOC and high – grade SOC.

These results indicate that the expression of c-met could not be used to differentiate the histopathological grading in serous ovarian carcinoma.


ovarian serous carcinoma, metastatic, C-met

Full Text:



Siegel RL, Miller KD, Jemal A. 2015. Cancer statistics. CA Cancer J Clin. 2015. . 65,: p. 5-29.

Wimberger P., Lehmann N., Kim-mig R., Burges A., Meier W., and Du Bois A. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsge-meinschaft Gynaekologische Onkologie ovarian cancer study group (AGO-OVAR). Gynecologic Oncology. 2007. 106(1): p. 69–74

Bottaro D. P., Rubin J. S., Faletto D. L. et al. Identification of the hepatocyte growth factor receptor as the met protooncogene product. Hepatology, 1991.. 251, p. 802–4.

Paulette M.F., Michelle A., and Tanja P. Review Articles: MET/HGF Signaling Pathway in Ovarian Carcinoma: Clinical Impli-cations and Future Direction. Hindawi Publishing Corporation Pathology Research International Volume 2012, Article ID 960327.

Organ S.L, Tsao M.S. An Overview of the c-met signaling pathway. Therapeutic Advances in Medical Oncology. 2001.

Basilico, C., Arnesano, A., Galluz-zo, M., Comoglio, P.M. and Michi-eli, P. A High Affinity Hepatocyte Growth Factor-Binding Site In The Immunoglobulin-Like Region Of Met. J Biol Chem. 2008. . 283,: p. 21267-77.

Birchmeier, C., Birchmeier, W., Gherardi, E. and Vande Woude, G.F. Met, Metastasis, Motility And More. Nat Rev Mol Cell Biol. 2003. . 4,: p. 915-25.

Trusolino, L. and Comoglio, P.M. Scatter factor and semaphorin re-ceptors: cell signalling for invasive growth. Nat Rev Cancer. 2002.. 2,: p. 289-300.

Sawada K., Radjabi A.R., Shino-miya N., Kistner E., Kenny H., Becker A.R., Turkyilmaz M.A., Salgia R.,Yamada S.D., Vande Woude G.F., et al. C Met Overex-pression Is A Prognostic Factor In Ovarian Cancer And An Effective Target For Inhibition Of Peri¬toneal Dissemination And Invasion. Can-cer Res. 2007.. 67, : p. 1670 9.

Liu Y., Metzinger M.N., Lewellen K.A., Crisps S.N., Carey K.D., Harper E.I., Shi Z., Tarwater L, Grisoli A., Lee E., Sluzars A., Yang J., Loughran E.A., Conley K., Johnson J.J., Klymenko Y., Bruney L., Liang Z., Dovichi N.J., Cheatham B., Leevy W.M., and Stack M.S. Obesity Contributes to Ovarian Cancer Metastatic Success through Increase Lipogenesis, En-hanced Vascularity, and Decreased Infiltration of M1 Macrophage. Cancer Res. 2015. . 75: p. 5046-57.

Ayhan A., Ertunc D., Tok E.C., Ayhan A. Expression of the c-Met in Ad-vanced Epithelial Ovarian Cancer and its prognostic significance. Int J Gynecol Cancer. 2005. 15: p. 618-23.

Lengyel, E. Ovarian cancer devel-opment and metastasis. Am J Pathol. 2010. 177,: p. 1053-64.

Fracchioli S, Katsaros D, Maggiora P, Di Renzo MF, Massobrio M. Evaluation of Ron and Met proto-oncogene expression in epithelial ovarian tumors [Abstract]. Minerva Ginecol. 1999. 51: p. 359–64.

Battista M.J., Schmidt M., Jakobi S., Cotarelo C., Almstedt K., Heimes A.S, Makris G.M., Weyer V., Lebrecht A., Hoffmann G., and Eichbaum M. C Met Is Overexpressed In Type I Ovarian Cancer:Results Of An Investigative Analysis In A Cohort Of Consecutive Ovarian Cancer Patients. Oncology Letters. 2016. . 12,: p. 2001-7.

Yamamoto S., Tsuda H., Miyai K., Takano M., Tamai S., and Matsub-ara O. Gene Amplification and Protein Overexpression of met are Common Events in Ovarian Clear cell Adenocar¬cinoma: Their Roles in Tumor Progression and Prognostication of the Patient. Mod Pathol. 2011. . 24, : p.1146 55.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Alamat Redaksi:
Pusat Pengembangan Penelitian, Fakultas Kedokteran Universitas Tadulako
Gedung Dekanat Fakultas Kedokteran Lantai 3, Universitas Tadulako
Jl. Soekarno Hatta KM. 9, Tondo, Mantiulore, Kota Palu, Sulawesi Tengah, Indonesia.
Email: redaksi.medpro@gmail.com
Telp: (0451) 422611 / HP : 085656320914

Flag Counter